[Rhythm and conduction disorders in familial myocardiopathy].

Arch Inst Cardiol Mex

Instituto Nacional de Cardiología, México.

Published: June 1989

Families of eight patients with the diagnosis of familiar cardiomyopathy were reviewed. It was possible to study 121 persons, 64 examined in the Instituto Nacional de Cardiología, and 57 through indirect questioning. It was found that in each of the families some disturbance in rhythm or conduction predominated. The evolution among the members of each family was similar, but was different in comparison with the other families. Those patients which presented complete A-V block died before 30 years of age, the majority of sudden death. The disturbances in rhythm or conduction most frequently observed were: complete A-V block, premature ventricular beats, lengthening of the Q-T, incomplete left bundle branch block, atrial fibrillation, Lown-Ganong-Levine syndrome, Wolff-Parkinson-White syndrome, premature supraventricular beats, incomplete right bundle branch block, ventricular fibrillation, and ventricular tachycardia. It can be concluded that: 1) familiar cardiomyopathy is, in reality, a group of distinct illnesses, with a genetic base; 2) the variability of the clinical findings, electrocardiography, and the evolution, depends on the particular type to which a given case corresponds; 3) it is possible that other varieties of familiar cardiomyopathy exist.

Download full-text PDF

Source

Publication Analysis

Top Keywords

familiar cardiomyopathy
12
families patients
8
rhythm conduction
8
complete a-v
8
a-v block
8
bundle branch
8
branch block
8
[rhythm conduction
4
conduction disorders
4
disorders familial
4

Similar Publications

In the modern era, cardiologists managing patients and families with cardiomyopathies need to be familiar with every stage of the diagnostic pathway from clinical phenotyping to the prescription and interpretation of genetic tests. This clinical consensus statement from the ESC Council for Cardiovascular Genomics aims to promote the integration of genetic testing into routine cardiac care of patients with cardiomyopathies, as recommended in the 2023 ESC guidelines for cardiomyopathies. The document describes the types of genetic tests currently available and provides advice on their prescription and for counselling after the return of genetic findings, including the approach in patients and families with variants of unknown significance.

View Article and Find Full Text PDF

Treatment options for hypertrophic obstructive cardiomyopathy: a patient-centric review.

Expert Rev Cardiovasc Ther

November 2024

Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', AORN dei Colli, Monaldi Hospital, Naples, Italy.

Article Synopsis
  • Hypertrophic cardiomyopathy (HCM) is a condition characterized by thickening of the heart's left ventricle walls, affecting 1 in 200-500 people, with 60% of cases being hereditary.
  • The review discusses various treatments for HCM, including medications (like beta-blockers and calcium channel blockers) and surgical options, along with the importance of personalized patient care in improving outcomes.
  • Future treatments, such as new drugs and gene therapies, are also highlighted, emphasizing the significance of tailoring management strategies to individual patient needs and preferences.
View Article and Find Full Text PDF

Cardiac amyloidosis.

Swiss Med Wkly

November 2024

Amyloidosis Network Zurich, University Hospital Zurich, Zurich, Switzerland.

Article Synopsis
  • * Symptoms resemble heart failure, and diagnosis relies on imaging tests like echocardiography and tissue biopsies to detect amyloid deposits.
  • * Treatment varies based on the type and severity, requiring a team of specialists for effective management and improved patient outcomes.
View Article and Find Full Text PDF

Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.

Circ Heart Fail

December 2024

Departments of Medicine, Radiology, and Pathology, Brigham and Women's Hospital, Boston, MA (R.Y.K., M.J.-H., P.J., C.Y.H.).

Background: Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition that can lead to atrial fibrillation, heart failure, and sudden cardiac death in many individuals but mild clinical impact in others. The mechanisms underlying this phenotypic heterogeneity are not well defined. The aim of this study was to use plasma proteomic profiling to help illuminate biomarkers that reflect or inform the heterogeneity observed in HCM.

View Article and Find Full Text PDF

Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.

J Card Fail

October 2024

Department of Cardiology, Inova Schar Heart and Vascular, Inova Schar Cancer, Falls Church, VA.

Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at increased risk of cardiovascular complications related to the cancer therapies. The presence of cardiomyopathy or heart failure in a patient with new cancer diagnosis portends a high risk for adverse oncology and cardiovascular outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!